Introducing Medication TargetingSM from Big Health and CVS Health®

Providing safe and effective non-drug options for mental health conditions

In collaboration with CVS Health®, all patients who fill a common mental health medication prescription are offered immediate access to Big Health’s digital therapeutics, Sleepio for insomnia and Daylight for anxiety, as an option alongside their medications.

“Big Health combines the safety and effectiveness of human therapy with the scalability and accessibility and equity of drugs.”

– Peter Hames, Big Health CEO

How Medication TargetingSM works

Through Big Health’s collaboration with CVS Health®, patients will now have access to Big Health’s two digital therapeutics: Sleepio for insomnia disorder and Daylight for generalized anxiety disorder.

Filling a critical gap in the mental health care space

Over 80% of mental health patients are treated with medications that often come with unpleasant and sometimes dangerous side effects1. However, behavioral interventions are widely considered a safer and equally effective option.

Medication targeting addresses these challenges by:

1. Offering cognitive behavioral techniques, the approach recommended as a first-line treatment for worry and anxiety by Anxiety & Depression Association of America.2
2. Providing treatment which has led to to 76% insomnia remission and 71% anxiety remission among participants in clinical trials.3, 4
3. Meeting the needs of the 75% of patients who would prefer a non-drug option to treat their mental health conditions.5

Learn how medication targeting can help your population

To discuss how Big Health can help you ensure that your employees have access to safe and effective non-drug treatments for mental health conditions, please fill out the form below.

During the COVID-19 public health emergency, Sleepio and Daylight are being made available as treatments for insomnia disorder and generalized anxiety disorder (GAD), respectively, without a prescription. Sleepio and Daylight have not been cleared by the U.S. Food and Drug Administration (FDA) for the treatment of insomnia disorder and GAD, respectively. Users are directed to not make any changes to their prescribed medication or other type of medical treatment without seeking professional medical advice.

Spark Direct is a digital program that may help individuals live well with major depressive disorder (MDD) and symptoms of depression by providing them with cognitive and behavioral techniques that can improve mood. Spark Direct has not been reviewed or approved by the Food & Drug Administration and is not intended to diagnose or treat any medical condition. Please read the instructions for use.

1. Terlizzi, E. P., & Norris, T. (1921). Mental health treatment among adults: United States, 2020.
2. American Psychiatric Association, D. S., & American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders: DSM-5 (Vol. 5). Washington, DC: American psychiatric association.
3. Espie, C. A., Kyle, S. D., Williams, C., Ong, J. C., Douglas, N. J., Hames, P., & Brown, J. S. (2012). A randomized, placebo-controlled trial of online cognitive behavioral therapy for chronic insomnia disorder delivered via an automated media-rich web application. Sleep, 35(6), 769-781.
4. Carl, J. R., Miller, C. B., Henry, A. L., Davis, M. L., Stott, R., Smits, J. A., … & Espie, C. A. (2020). Efficacy of digital cognitive behavioral therapy for moderate‐to‐severe symptoms of generalized anxiety disorder: A randomized controlled trial. Depression and anxiety, 37(12), 1168-1178.
5. McHugh, R. K., Whitton, S. W., Peckham, A. D., Welge, J. A., & Otto, M. W. (2013). Patient preference for psychological vs pharmacologic treatment of psychiatric disorders: a meta-analytic review. The Journal of clinical psychiatry, 74(6), 13979.
Sleepio and Daylight are available as an adjunct to usual medical care for insomnia disorder or generalized anxiety disorder, respectively, for adults ages 18 and older, without FDA review under their COVID-19 policy. Users are directed to not make any changes to their prescribed medication or other type of medical treatment without seeking professional medical advice.

DOC-1317 Effective 05/2022.